Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia

Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia

Sanjay K Bajpai,1 M Janelle Cambron-Mellott,2 Oliver Will,2 Jiat-Ling Poon,1 Qianqian Wang,1 Beth D Mitchell,1 Eugenia Y Peck,2 Jane Babrowicz,2 Nedina K Raibulet,1 Christopher J Child,1 Kathleen Beusterien2 1Eli Lilly and Company, Indianapolis, IN, USA; 2Cerner Enviza, New York, NY, USACorresponden...

Full description

Bibliographic Details
Main Authors: Bajpai SK, Cambron-Mellott MJ, Will O, Poon JL, Wang Q, Mitchell BD, Peck EY, Babrowicz J, Raibulet NK, Child CJ, Beusterien K
Format: Article
Language:English
Published: Dove Medical Press 2022-11-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
diabetes
severe hypoglycemic events
glucagon delivery device
patient attitudes
Online Access:https://www.dovepress.com/development-of-a-measure-to-assess-attitudes-towards-nasal-versus-auto-peer-reviewed-fulltext-article-DMSO

Internet

https://www.dovepress.com/development-of-a-measure-to-assess-attitudes-towards-nasal-versus-auto-peer-reviewed-fulltext-article-DMSO

Similar Items